Thymogen
Immunomodulatory Dipeptide
Also known as L-Glu-L-Trp (glutamyl-tryptophan)
Thymogen is the dipeptide L-glutamyl-L-tryptophan, studied in research on immune modulation and, in rodent models, on carcinogenesis endpoints.
Mix & Match
1 vial — no vial discount yet.
Add 2 more vials for 5% off.
After that, 10% at 5 vials, 20% at 10 vials.
This product is intended strictly for laboratory research use within the United States. It is not approved by the FDA for the diagnosis, treatment, cure, or prevention of any disease. Not for human or veterinary use.
By purchasing, you confirm the material will be used solely for lawful research purposes in accordance with applicable U.S. federal, state, and local regulations.
Thymogen is the dipeptide L-glutamyl-L-tryptophan, studied in research on immune modulation and, in rodent models, on carcinogenesis endpoints.
Experimental work examines natural-killer-cell activity and immune-system behaviour under controlled conditions.
Third-party tested for purity, ID, quantity.
Coming Soon
The certificate of analysis for the 20mg lot is being finalised and will be published here as soon as the lab returns it.
Thymogen is a two-residue peptide derived from thymic peptide research. Published studies have reported that the synthetic dipeptide slows age-related change and inhibits spontaneous carcinogenesis in rats, and that natural-killer-cell cytolytic activity is required for its in vivo antitumour effect.
Additional work covers oral absorption enhancement through lipid and glycosyl conjugation, and analogues evaluated in liver-damage models.
Thymogen originated in research on thymic peptide preparations, from which the active dipeptide was isolated and synthesized.
Work from the 1990s onward characterized its immunomodulatory profile across infection, oncology, and surgical research models, giving it an unusually broad literature for a dipeptide.
Research into the Glu-Trp dipeptide focuses on immunomodulation and NK-cell-dependent antitumour activity. Frameworks evaluate carcinogenesis endpoints, immune-cell function, and peptide delivery chemistry under controlled preclinical conditions.
4 of the 4 areas below are addressed directly by a paper cited on this page.
Immunomodulation and NK-cell activity models
Addressed on this page by Smith 2003. Each is linked to its source record in the references below, so what was measured — and in what system — can be read rather than taken on trust.
- Smith, DL. et al. (2003) — Natural killer cell cytolytic activity is necessary for in vivo antitumor activity of the dipeptide L-glutamyl-L-tryptophan
Carcinogenesis endpoint research
Addressed on this page by Anisimov 2000. Each is linked to its source record in the references below, so what was measured — and in what system — can be read rather than taken on trust.
- Anisimov, VN. et al. (2000) — Immunomodulatory synthetic dipeptide L-Glu-L-Trp slows down aging and inhibits spontaneous carcinogenesis in rats
Peptide oral-absorption chemistry
Addressed on this page by Bergeon 2008, Anisimov 2000, Smith 2003. Each is linked to its source record in the references below, so what was measured — and in what system — can be read rather than taken on trust.
- Bergeon, JA. et al. (2008) — Oral absorption enhancement of dipeptide L-Glu-L-Trp-OH by lipid and glycosyl conjugation
- Anisimov, VN. et al. (2000) — Immunomodulatory synthetic dipeptide L-Glu-L-Trp slows down aging and inhibits spontaneous carcinogenesis in rats
- Smith, DL. et al. (2003) — Natural killer cell cytolytic activity is necessary for in vivo antitumor activity of the dipeptide L-glutamyl-L-tryptophan
Thymic peptide structure-activity studies
Addressed on this page by Anisimov 2000, Smith 2003, Bergeon 2008. Each is linked to its source record in the references below, so what was measured — and in what system — can be read rather than taken on trust.
- Anisimov, VN. et al. (2000) — Immunomodulatory synthetic dipeptide L-Glu-L-Trp slows down aging and inhibits spontaneous carcinogenesis in rats
- Smith, DL. et al. (2003) — Natural killer cell cytolytic activity is necessary for in vivo antitumor activity of the dipeptide L-glutamyl-L-tryptophan
- Bergeon, JA. et al. (2008) — Oral absorption enhancement of dipeptide L-Glu-L-Trp-OH by lipid and glycosyl conjugation
The references section of this page cites 4 primary papers published between 2000 and 2023 — a limited but non-trivial record. Every citation is linked to its PubMed or DOI record so it can be read rather than taken on trust, and the summaries above describe what those papers report rather than what the compound is claimed to do.
Research compounds attract claims that outrun their evidence. Below are the ones most often encountered for Thymogen, set against what the papers cited on this page actually report. Where the record is thin or contested, that is stated rather than smoothed over.
Thymogen is commonly described online in connection with stronger immune function and resistance to infection. In the research literature the same compound is filed under immunomodulation and NK-cell activity models, carcinogenesis endpoint research and peptide oral-absorption chemistry.
The 4 papers cited on this page, published between 2000 and 2023 (1 in animal models) describe laboratory and animal work. None reports a controlled trial in humans. Findings in cell culture or in a rodent model describe what happened in that system; they do not establish that the same occurs in humans, and this compound is not approved for human use.
Nothing above is a statement of what this material does. It is a summary of what has been published and what has not. Eppix Labs supplies research materials only and provides no dosing, administration or protocol guidance.
Every lot of Thymogen is independently assayed before it is released, and the certificate for the lot shipped is published rather than summarised. Where a certificate for a current lot is not yet posted, the lot has not yet been released against it.
Researchers who buy Thymogen in the United States through Eppix Labs receive a batch-labelled vial whose certificate is published against that lot code, so the material can be matched to its analysis rather than to a generic specification.
- Lyophilized storage
- −20 °C long-term; stable at room temperature in transit
- After reconstitution
- 2–8 °C
- Light
- Protect from UV and direct light
- Freeze-thaw
- Avoid repeated cycles
- Vehicle
- Bacteriostatic water in most published protocols
- Format
- Lyophilized powder
Thymogen is supplied as lyophilized powder. In the dry state the material is comparatively stable, which is why it ships at ambient temperature without a cold chain; once reconstituted it is a peptide in solution and the handling constraints tighten considerably. At 2 residues it is short enough to be produced by solid-phase synthesis, and the published sequence on this page is what an identity assay is checked against.
Repeated freeze-thaw cycling is the handling error most likely to degrade material of this class, because each cycle concentrates solutes at the ice boundary. Where a protocol calls for the same vial across multiple sessions, the published literature generally describes aliquoting after reconstitution rather than re-freezing the whole volume.
Vials may appear empty on arrival. Lyophilized material collects at the base of the vial and is often not visible until the vial is inspected under direct light.
- 1 × sealed glass vial in the strength selected (20mg / Single Vial, 20mg / 5-Pack, 20mg / 10-Pack available), batch-labelled
- Batch documentation for the lot shipped, once its certificate is published
- Discreet outer packaging with no product names on the exterior
- FedEx, tracked, typically 1–3 business days domestically
- Bacteriostatic water or any other reconstitution vehicle
- Syringes, needles or filters
- Dosing, administration or protocol guidance of any kind
Reconstitution materials are sourced separately. The reconstitution calculator on this site works out concentrations for a given volume, but it is an arithmetic tool for laboratory record-keeping and not a protocol.
No. Eppix Labs products are supplied exclusively for laboratory research. We do not provide dosing, administration, or usage guidance.
Each unit contains the labeled quantity of Thymogen. Independent third-party analysis verifies purity, identity, and net content per batch.
The unit contains only the research compound. Any laboratory materials required for reconstitution or experimental procedures must be sourced separately.
Duration depends entirely on research design, storage conditions, and laboratory protocol.
Immunomodulatory synthetic dipeptide L-Glu-L-Trp slows down aging and inhibits spontaneous carcinogenesis in rats
PubMedNatural killer cell cytolytic activity is necessary for in vivo antitumor activity of the dipeptide L-glutamyl-L-tryptophan
PubMedOral absorption enhancement of dipeptide L-Glu-L-Trp-OH by lipid and glycosyl conjugation
PubMedReparative and Antioxidant Effects of New Analogues of Immunomodulator Thymogen in Experimental Model of Liver Damage
PubMedRelated
You May Also Like
Next-generation GLP receptor agonist studied for metabolic signaling and nutrient partitioning pathways
From$79.99
Dual incretin receptor agonist studied for glucose regulation, metabolic signaling, and weight pathway research
From$39.99
Studied in metabolic research for its effects on glucose regulation, appetite signaling, and energy balance.
From$59.99
Long-acting amylin analog engineered for appetite signaling, metabolic control, and energy balance research
From$99.99